The content on this site is intended for healthcare professionals only
Dr Bisogno presents results at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting from a randomised phase III clinical trial of 6 months maintenance chemotherapy for children with the rare disease rhabdomyosarcoma.
For those receiving the low dose chemotherapy following initial treatments, 5 year overall survival improved from 73.7% to 86.5%, which is the first improvement in this indication for more than 30 years.
For more detail, watch Dr Bisogno speak with ecancer about the trial here, or read our news coverage here.
Slides from this presentation are available here.
KEYNOTE-756 trial shows increased response in ER+/HER2- breast cancer
Feasibility and safety of boost at 74 Gy based on interim FDG-PET during thoracic radio-chemotherapy for NSCLC patients
Adjuvant radiotherapy has no benefit following radical prostatectomy
Neoadjuvant cemiplimab shows favourable event-free, disease-free and overall survival rates in patients with resectable CSCC
Adagrasib shows durable clinical benefit in advanced KRAS-mutant NSCLC
OncoAlert Round Up for September 15-21, 2023
The 5-year long-term outcomes of radiation technique for locally advanced NSCLC
The Southeast Asian Breast Cancer Symposium; background, aims and successes
OncoAlert Round Up for August 25th - 31st, 2023
